



SuperGen Completes Contract to Transition Wyeth Distribution of Nipent(R), Outside of the U.S.

DUBLIN, Calif., June 6 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG) today announced that a contract has been executed to terminate the distribution of Nipent® (pentostatin for injection) by Wyeth and transition distribution to SuperGen, Inc. The Company paid Wyeth a \$2.1 million dollar early termination fee, making it effective June 1, 2006. SuperGen and Wyeth will collaborate to ensure uninterrupted distribution services during the transition period. Distribution and marketing for Nipent in Europe will be managed by SuperGen's subsidiary, EuroGen Pharmaceuticals Limited, which is based in Cheltenham, United Kingdom.

EuroGen will have a commercial presence at the upcoming European Hematology Association (EHA) meeting in Amsterdam, The Netherlands. Additionally Nipent will be discussed within a symposium on June 15 at EHA entitled "M.D. Anderson Cancer Center Approach to Patients with Hematological Malignancies," chaired by Michael J. Keating, M.D.

About Nipent

Nipent® (pentostatin for injection) is currently approved as a single- agent treatment for patients with Hairy Cell Leukemia in the United States and selective counties within Europe, and is not approved as either a single agent or as part of a combination regimen for treatment for any other indication in any territory.

About SuperGen

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. SuperGen's portfolio includes Orathecin™ (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent® (pentostatin for injection), Mitomycin, and Surface Safe® cleaner. In addition, a number of aurora-A, tyrosine kinase and DNA methyltransferase inhibitors are under development. For more information about SuperGen, please visit <http://www.supergen.com>.

Contacts:

SuperGen
Timothy L. Enns
S.V.P., Corporate Communications
& Business Development
Tel: (925) 560-0100 x111
E-mail: tenns@supergen.com

Noonan Russo
Sharon Weinstein
Director of Investor Relations
Tel: (212) 845-4271
E-mail: sharon.weinstein@eurorscg.com

SOURCE SuperGen, Inc.
/Web site: <http://www.supergen.com>
(SUPG)